Investor Presentation Q1 2023

Novo Nordisk volume market shares in the three insulin segments 130 Investor presentation First three months of 2023 NAO 60% Long-acting insulin Premix insulin Fast-acting insulin tMU MS tMU MS tMU MS 100 80% 80 88 80% 80 100% CAGR volume1: -0.8% CAGR volume1: -7.9% CAGR volume1: 1.4% MI penetration2: 64.7% 00 MI penetration²: 47.3% MI penetration²: 84.1% 80 80% 60% 60 60% 60 60 60 40 40 20 20 40% 40 20% 20 40% 40 20% 20 40% 20% 0% Feb 2023 Segment volume -NovoRapidⓇ NN combined 0 Feb 0% 0 0% 0 Feb Feb Feb Feb 2018 2023 2018 2023 2018 Segment volume -LevemirⓇ Segment volume -TresibaⓇ -Combined -NovoLogⓇ Mix share 70/30 FiaspⓇ 1 CAGR for 5-year period; 2 Includes new-generation insulin. MI: Modern insulin; MS: Market Share; NN: Novo Nordisk; tMU: Thousand mega units Source: IQVIA monthly MAT, Feb 2023 volume figures

View entire presentation